Ferring Pharma Names Aaron Graff As Chief Executive Officer Of U.S. Holding Company

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced that Aaron Graff has been appointed Chief Executive Officer of Ferring Holding Inc. In this role Mr. Graff assumes direct responsibility for all Ferring US activities including commercial operations (Ferring Pharmaceuticals Inc.), clinical development (Ferring International PharmaScience Center US), and manufacturing (Ferring Production Inc.).

"A US-based CEO helps ensure that important decisions concerning the US business benefit from the insight that only close proximity to the market provides"

"A US-based CEO helps ensure that important decisions concerning the US business benefit from the insight that only close proximity to the market provides," comments Mr. Graff.

As CEO, Mr. Graff reports to the board of directors of Ferring Holding Company Inc., chaired by Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Group.

Since joining Ferring Pharmaceuticals Inc. as President and Chief Operating Officer in 2010, Mr. Graff has overseen consistent double-digit annual growth in the US subsidiary and the expansion of its US presence to include an integrated operations center. This center, located in Parsippany, New Jersey, includes product development, manufacturing, commercial and all necessary medical, regulatory, and support functions.

Originally from Niagara Falls, New York, Mr. Graff joined Ferring in 2002 as Vice President, Global Marketing and Business Development based in Denmark. He later became Senior Vice President, Asia Region and Global Marketing based at the company's global headquarters in Switzerland.

Prior to joining Ferring, Mr. Graff worked for over 17 years at Bristol-Myers Squibb in both the USA and Europe. His responsibilities included a broad variety of commercial positions in prescription pharmaceuticals and non-prescription medicines.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

© 2016 Ferring B.V.

Contacts

Ferring Pharmaceuticals
Patrick Gorman, 862-286-5035
[email protected]

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.